Multiple myeloma

@article{Raab2009MultipleM,
  title={Multiple myeloma},
  author={Marc S Raab and Klaus Podar and Iris Breitkreutz and Paul G. Richardson and Kenneth C. Anderson},
  journal={The Lancet},
  year={2009},
  volume={374},
  pages={324-339}
}
Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis. This knowledge has already expanded treatment options for patients with multiple myeloma. Prototypic drugs thalidomide, bortezomib, and lenalidomide have each been approved for the treatment of this disease by targeting both multiple myeloma cells and the bone marrow microenvironment… Expand
Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.
TLDR
The mechanisms underlying the anti-myeloma activities of the potent BCL-2 family protein inhibitors, individually or in combination with conventional therapeutic options, are summarized and an overview of the strong rationale to clinically investigate such interventions for MM therapy is provided. Expand
Molecular Biology of Multiple Myeloma
Multiple myeloma is a disease of malignant plasma cells in the bone marrow. Interaction of malignant plasma cells with the bone marrow microenvironment plays a key role in the pathogenesis ofExpand
Animal Models of Multiple Myeloma Bone Disease
TLDR
Cumulative evidence shows that the interaction of MM cells and bone microenvironment plays a significant role in MM progression, suggesting that these interactions may be good targets for therapy. Expand
Achieving Complete Response in Multiple Myeloma: Do We Need to Change the Definition?
TLDR
The European Group for Blood and Marrow Transplant (EBMT) and International Myeloma Working Group (IMWG) uniform criteria seem to be inadequate to evaluate treatment response and further studies on more sensitive tools are necessary for more accurate disease status evaluation. Expand
Overcoming bortezomib resistance in multiple myeloma.
TLDR
The mechanisms by which bortezomib resistance occurs in MM, including inherent and acquired mutation, and inducible pro-survival signalling are explored, as well as some potential druggable targets within this milieu. Expand
CCR New Strategies New Strategies in the Treatment of Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a rare type of non-Hodgkin lymphoma that traditionally has been thought to possess the poor-risk features of both indolent lymphoma, with its incurability, andExpand
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
TLDR
It is suggested that tumor microenvironment-derived GDF15 is a key survival and chemoprotective factor for multiple myeloma cells, which is pathophysiologically linked to both initial parameters of the disease as well as patient survival. Expand
Management of myeloma-associated renal dysfunction in the era of novel therapies
TLDR
Bortezomib, lenalidomide and thalidomides are considered first-line therapies in induction, maintenance and salvage therapy for MM and can improve outcome in patients with RI, especially when combined, and bortzomib with dexamethasone may have a renal protective effect. Expand
MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
TLDR
It was found that in myeloma cell lines, MYC gene amplifications were common and correlated with MYC mRNA and protein, supporting that the activity of 10058-F4 was through specific inhibition of MYC. Expand
Presentation and risk stratification--improving prognosis for patients with multiple myeloma.
  • S. Lonial
  • Medicine
  • Cancer treatment reviews
  • 2010
TLDR
Results of a number of studies indicate that the use of novel therapies in both the induction and maintenance settings, accompanied by risk stratification, may improve prognosis for patients with MM. Expand
...
1
2
3
4
5
...